# Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

> **NCT01401933** · PHASE1 · COMPLETED · sponsor: **Abbott** · enrollment: 14 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Linifanib
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT01401933
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01401933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01401933, "Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01401933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*